Loading...

La Jolla Pharmaceutical

Nasdaq:LJPC
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LJPC
Nasdaq
$250M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The last earnings update was 70 days ago. More info.


Add to Portfolio Compare Print
  • La Jolla Pharmaceutical has significant price volatility in the past 3 months.
LJPC Share Price and Events
7 Day Returns
-2.3%
NasdaqCM:LJPC
-2.3%
US Biotechs
0.8%
US Market
1 Year Returns
-69.6%
NasdaqCM:LJPC
-11.9%
US Biotechs
4.8%
US Market
LJPC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
La Jolla Pharmaceutical (LJPC) -2.3% -4.8% 23.2% -69.6% -43.6% -15.8%
US Biotechs -2.3% 2.3% -4.3% -11.9% 8.5% 10.3%
US Market 0.8% 4.3% 2.8% 4.8% 37.9% 43.5%
1 Year Return vs Industry and Market
  • LJPC underperformed the Biotechs industry which returned -11.9% over the past year.
  • LJPC underperformed the Market in United States of America which returned 4.8% over the past year.
Price Volatility
LJPC
Industry
5yr Volatility vs Market
Related Companies

LJPC Value

 Is La Jolla Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of La Jolla Pharmaceutical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for La Jolla Pharmaceutical.

NasdaqCM:LJPC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 12.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:LJPC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.33
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.327 (1 + (1- 21%) (62.1%))
1.655
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.65
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.655 * 5.96%)
12.59%

Discounted Cash Flow Calculation for NasdaqCM:LJPC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for La Jolla Pharmaceutical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqCM:LJPC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 12.59%)
2020 -9.00 Analyst x1 -7.99
2021 33.00 Analyst x1 26.03
2022 115.00 Analyst x1 80.57
2023 198.00 Analyst x1 123.20
2024 273.18 Est @ 37.97% 150.97
2025 348.02 Est @ 27.4% 170.82
2026 417.61 Est @ 20% 182.05
2027 479.49 Est @ 14.82% 185.64
2028 533.15 Est @ 11.19% 183.33
2029 579.28 Est @ 8.65% 176.91
Present value of next 10 years cash flows $1,271.53
NasdaqCM:LJPC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $579.28 × (1 + 2.73%) ÷ (12.59% – 2.73%)
$6,033.44
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $6,033.44 ÷ (1 + 12.59%)10
$1,842.65
NasdaqCM:LJPC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,271.53 + $1,842.65
$3,114.18
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,114.18 / 27.10
$114.92
NasdaqCM:LJPC Discount to Share Price
Calculation Result
Value per share (USD) From above. $114.92
Current discount Discount to share price of $9.24
= -1 x ($9.24 - $114.92) / $114.92
92%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price La Jolla Pharmaceutical is available for.
Intrinsic value
>50%
Share price is $9.24 vs Future cash flow value of $114.92
Current Discount Checks
For La Jolla Pharmaceutical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • La Jolla Pharmaceutical's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • La Jolla Pharmaceutical's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for La Jolla Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are La Jolla Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:LJPC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-6.82
NasdaqCM:LJPC Share Price ** NasdaqCM (2019-07-15) in USD $9.24
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 18.01x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of La Jolla Pharmaceutical.

NasdaqCM:LJPC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:LJPC Share Price ÷ EPS (both in USD)

= 9.24 ÷ -6.82

-1.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • La Jolla Pharmaceutical is loss making, we can't compare its value to the US Biotechs industry average.
  • La Jolla Pharmaceutical is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does La Jolla Pharmaceutical's expected growth come at a high price?
Raw Data
NasdaqCM:LJPC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
48.2%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.81x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for La Jolla Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on La Jolla Pharmaceutical's assets?
Raw Data
NasdaqCM:LJPC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.27
NasdaqCM:LJPC Share Price * NasdaqCM (2019-07-15) in USD $9.24
United States of America Biotechs Industry PB Ratio Median Figure of 436 Publicly-Listed Biotechs Companies 2.98x
United States of America Market PB Ratio Median Figure of 5,240 Publicly-Listed Companies 1.81x
NasdaqCM:LJPC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:LJPC Share Price ÷ Book Value per Share (both in USD)

= 9.24 ÷ 0.27

33.85x

* Primary Listing of La Jolla Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • La Jolla Pharmaceutical is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess La Jolla Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. La Jolla Pharmaceutical has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LJPC Future Performance

 How is La Jolla Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is La Jolla Pharmaceutical expected to grow at an attractive rate?
  • La Jolla Pharmaceutical's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • La Jolla Pharmaceutical's earnings growth is expected to exceed the United States of America market average.
  • La Jolla Pharmaceutical's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:LJPC Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:LJPC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 48.2%
NasdaqCM:LJPC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 40.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.2%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:LJPC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:LJPC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 168 63 2
2022-12-31 105 -20 2
2021-12-31 71 -65 2
2020-12-31 72 -70 -88 4
2019-12-31 25 -88 -123 3
NasdaqCM:LJPC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 14 -139 -181
2018-12-31 10 -152 -199
2018-09-30 6 -145 -193
2018-06-30 2 -127 -168
2018-03-31 1 -109 -142
2017-12-31 -85 -115
2017-09-30 0 -78 -101
2017-06-30 0 -75 -96
2017-03-31 0 -68 -85
2016-12-31 1 -59 -78
2016-09-30 1 -49 -65
2016-06-30 2 -39 -54

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • La Jolla Pharmaceutical's earnings are expected to grow significantly at over 20% yearly.
  • La Jolla Pharmaceutical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:LJPC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from La Jolla Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:LJPC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.27 1.70 0.83 2.00
2022-12-31 -0.52 0.40 -1.23 3.00
2021-12-31 -1.85 -1.44 -2.45 3.00
2020-12-31 -2.53 -1.45 -3.25 4.00
2019-12-31 -4.51 -4.30 -4.70 3.00
NasdaqCM:LJPC Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -6.82
2018-12-31 -7.85
2018-09-30 -7.92
2018-06-30 -7.21
2018-03-31 -6.37
2017-12-31 -5.41
2017-09-30 -5.06
2017-06-30 -5.12
2017-03-31 -4.85
2016-12-31 -4.54
2016-09-30 -3.78
2016-06-30 -3.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if La Jolla Pharmaceutical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess La Jolla Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
La Jolla Pharmaceutical has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LJPC Past Performance

  How has La Jolla Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare La Jolla Pharmaceutical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • La Jolla Pharmaceutical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare La Jolla Pharmaceutical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare La Jolla Pharmaceutical's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
La Jolla Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from La Jolla Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:LJPC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 13.64 -180.63 72.07
2018-12-31 10.06 -199.47 82.76
2018-09-30 5.87 -192.60 78.26
2018-06-30 2.40 -168.14 64.51
2018-03-31 0.81 -142.09 48.37
2017-12-31 -114.80 30.85
2017-09-30 0.09 -101.14 23.75
2017-06-30 0.13 -96.11 20.71
2017-03-31 0.38 -84.94 18.15
2016-12-31 0.62 -78.19 16.70
2016-09-30 0.94 -65.13 14.68
2016-06-30 1.54 -54.35 13.68
2016-03-31 1.29 -49.44 14.19
2015-12-31 1.06 -41.91 13.93
2015-09-30 0.65 -36.93 14.26
2015-06-30 -31.51 13.34 -0.55
2015-03-31 -25.14 12.06 -2.00
2014-12-31 -21.31 11.40
2014-09-30 -20.86 12.60 2.06
2014-06-30 -20.22 13.39 3.56
2014-03-31 -19.57 13.17 5.70
2013-12-31 -18.74 13.58
2013-09-30 -15.94 12.14 2.81
2013-06-30 -13.95 11.88 2.34
2013-03-31 -17.91 12.30 1.97
2012-12-31 -8.52 9.39 1.35
2012-09-30 -18.43 6.95 0.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if La Jolla Pharmaceutical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if La Jolla Pharmaceutical has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if La Jolla Pharmaceutical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess La Jolla Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
La Jolla Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LJPC Health

 How is La Jolla Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up La Jolla Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • La Jolla Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • La Jolla Pharmaceutical's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of La Jolla Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from La Jolla Pharmaceutical Company Filings, last reported 3 months ago.

NasdaqCM:LJPC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 11.30 124.34 140.02
2018-12-31 35.92 124.32 172.60
2018-09-30 74.99 124.32 204.34
2018-06-30 115.67 124.30 241.43
2018-03-31 157.41 0.00 154.41
2017-12-31 88.20 0.00 90.92
2017-09-30 119.80 0.00 120.84
2017-06-30 140.32 0.00 141.32
2017-03-31 162.33 0.00 162.38
2016-12-31 61.04 0.00 65.73
2016-09-30 82.29 0.00 85.04
2016-06-30 99.61 0.00 100.56
2016-03-31 111.84 0.00 113.07
2015-12-31 124.53 0.00 126.47
2015-09-30 133.60 0.00 135.06
2015-06-30 36.19 0.00 36.05
2015-03-31 42.96 0.00 42.71
2014-12-31 48.46 0.00 48.56
2014-09-30 52.82 0.00 54.13
2014-06-30 3.09 0.00 3.89
2014-03-31 5.22 0.00 5.89
2013-12-31 7.65 0.00 8.63
2013-09-30 10.24 0.00 10.70
2013-06-30 1.68 0.00 1.84
2013-03-31 2.54 0.00 2.70
2012-12-31 3.21 0.00 3.41
2012-09-30 -9.53 0.00 3.36
  • La Jolla Pharmaceutical's level of debt (1100.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1100.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • La Jolla Pharmaceutical has less than a year of cash runway based on current free cash flow.
  • La Jolla Pharmaceutical has less than a year of cash runway if free cash flow continues to grow at historical rates of 46% each year.
X
Financial health checks
We assess La Jolla Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. La Jolla Pharmaceutical has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LJPC Dividends

 What is La Jolla Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from La Jolla Pharmaceutical dividends.
If you bought $2,000 of La Jolla Pharmaceutical shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate La Jolla Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate La Jolla Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:LJPC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2018 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:LJPC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as La Jolla Pharmaceutical has not reported any payouts.
  • Unable to verify if La Jolla Pharmaceutical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of La Jolla Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as La Jolla Pharmaceutical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess La Jolla Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can La Jolla Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. La Jolla Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LJPC Management

 What is the CEO of La Jolla Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
George Tidmarsh
COMPENSATION $1,509,081
AGE 59
TENURE AS CEO 7.5 years
CEO Bio

Dr. George F. Tidmarsh, M.D., Ph.D., has been the Chief Executive Officer, President and Secretary of La Jolla Pharmaceutical Company since January 19, 2012. Dr. Tidmarsh has experience creating, building and leading biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2005, Dr. Tidmarsh founded Horizon Pharma, Inc., where he served as President and Chief Executive Officer until 2008 and as a Director and consultant until 2011. He founded Nuveta Inc. and served as its President and Chief Executive Officer. He founded Metronome Therapeutics Inc., in 2006, where he served as its Chief Executive Officer until its acquisition by Spectrum Pharmaceuticals, Inc. in 2010. He served as the Chief Executive Officer of Solana Therapeutics, Inc. from 2011 to 2012. He Co-founded Horizon Pharma USA Inc. in 2005 and served as its Scientific Consultant and Chief Executive Officer from 2005 to 2008, where he led all aspects of development of Duexa, which was approved by the FDA for the treatment of rheumatoid arthritis. He served as the Senior Vice President, Head of Research and Development Operations and Chief Scientific Officer at Spectrum Pharmaceuticals, Inc. from July 2010 to June 13, 2011. Dr. Tidmarsh founded Threshold Pharmaceuticals Inc. in 2001 and served as its Consultant since March 31, 2006 and as its President from October 2001 to August 2005. He has more than 22 years of entrepreneurial and executive experience in Biotechnology. From April 2001 to September 2001, Dr. Tidmarsh served as an Entrepreneur-in-residence at Three Arch Partners. From October 1996 to December 2000, he served various positions at Coulter Pharmaceuticals, Inc., including as Chief Medical Officer since September 1998. Earlier in his career, Dr. Tidmarsh held various scientific and clinical positions at Sequus Pharmaceuticals, Inc., Gilead Sciences, Inc. and SyStemix, Inc.He has been involved in numerous successful startups, FDA drug approvals and IPO's. Dr. Tidmarsh has 22 years of experience in biotechnology, including the successful clinical development of three FDA-approved drugs (BEXXAR and Doxil). Dr. Tidmarsh led the development of Doxil® (doxorubicin hydrochloride liposomal injection) while serving as Director of Oncology at Liposome Technology, Inc. He served as the Chairman and Member of the Clinical Advisory Board at Threshold Pharmaceuticals, Inc. He has been a Director of La Jolla Pharmaceutical Company since January 2012. He served as a Member of Advisory Board at Threshold Pharmaceuticals Inc. He served as an Executive Director of Anavex Life Sciences Corp. from October 12, 2011 to March 17, 2012. He served as a Director of Threshold Pharmaceuticals, Inc. from October 2001 to March 31, 2006; Nuveta, Inc. and Horizon Pharma USA, Inc. He serves as Clinical Staff Member of Stanford Childrens Hospital and El Camino Hospital. He serves as a director of the Citizens Oncology Foundation. He serves as Consulting Professor of Pediatrics and Neonatology at Stanford University School of Medicine. He has been a Director at Odonate Therapeutics, Inc. since December 2016. He is an author of 20 peer-reviewed scientific papers published in leading journals. He completed fellowship training in Pediatric Oncology and Neonatology at Neonatal Intensive Care of Stanford University School of Medicine and remains a member of the Adjunct Faculty in Pediatrics and Neonatology. Dr. Tidmarsh has M.D. and Ph.D. from the Stanford University School of Medicine. He received his B.S. degree in Microbiology from Stanford University.

CEO Compensation
  • George's compensation has been consistent with company performance over the past year, both up more than 20%.
  • George's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the La Jolla Pharmaceutical management team in years:

3.3
Average Tenure
54.5
Average Age
  • The tenure for the La Jolla Pharmaceutical management team is about average.
Management Team

George Tidmarsh

TITLE
President
COMPENSATION
$2M
AGE
59
TENURE
7.5 yrs

Jennifer Carver

TITLE
Chief Operating Officer
COMPENSATION
$787K
AGE
65
TENURE
2.5 yrs

Mink Chawla

TITLE
Chief Medical Officer
COMPENSATION
$782K
AGE
48
TENURE
4 yrs

Dennis Mulroy

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
64
TENURE
4.3 yrs

James Rolke

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
50
TENURE
2.5 yrs

Sandra Vedrick

TITLE
Director of Investor Relations & Human Resources

Darryl Wellinghoff

TITLE
Chief Commercial Officer
AGE
50
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the La Jolla Pharmaceutical board of directors in years:

5.2
Average Tenure
57
Average Age
  • The tenure for the La Jolla Pharmaceutical board of directors is about average.
Board of Directors

Kevin Tang

TITLE
Chairman of the Board
COMPENSATION
$53K
AGE
52
TENURE
4.9 yrs

George Tidmarsh

TITLE
President
COMPENSATION
$2M
AGE
59
TENURE
7.5 yrs

Craig Johnson

TITLE
Director
COMPENSATION
$133K
AGE
57
TENURE
5.8 yrs

Laura Douglass

TITLE
Director
COMPENSATION
$113K
AGE
54
TENURE
5.8 yrs

Tom Ganz

TITLE
Member of Scientific Advisory Board
TENURE
5.4 yrs

Elizabeta Nemeth

TITLE
Member of Scientific Advisory Board
TENURE
5.4 yrs

Robert Rosen

TITLE
Director
COMPENSATION
$113K
AGE
63
TENURE
5 yrs

Paul Adams

TITLE
Member of Advisory Board
TENURE
4.3 yrs

Victor Gordeuk

TITLE
Member of Advisory Board
TENURE
4.3 yrs

Ashutosh Lal

TITLE
Member of Advisory Board
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
31. Jan 19 Buy Lakhmir Chawla Individual 29. Jan 19 30. Jan 19 3,000 $5.57 $16,694
10. Jan 19 Buy Tang Capital Management, LLC Company 07. Jan 19 09. Jan 19 1,300,000 $5.84 $6,985,285
10. Jan 19 Sell Perceptive Advisors LLC Company 07. Jan 19 08. Jan 19 -2,060,235 $9.52 $-11,715,985
10. Jan 19 Buy George Tidmarsh Individual 07. Jan 19 07. Jan 19 2,000 $5.85 $11,700
10. Jan 19 Buy Jennifer Carver Individual 09. Jan 19 09. Jan 19 5,000 $6.19 $30,825
10. Jan 19 Buy James Rolke Individual 09. Jan 19 09. Jan 19 1,600 $6.10 $9,746
21. Aug 18 Buy James Rolke Individual 16. Aug 18 16. Aug 18 1,000 $22.00 $21,997
21. Aug 18 Buy Jennifer Carver Individual 16. Aug 18 16. Aug 18 1,000 $20.90 $20,895
X
Management checks
We assess La Jolla Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. La Jolla Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LJPC News

Simply Wall St News

If You Had Bought La Jolla Pharmaceutical (NASDAQ:LJPC) Stock A Year Ago, You'd Be Sitting On A 82% Loss, Today

So spare a thought for the long term shareholders of La Jolla Pharmaceutical Company (NASDAQ:LJPC); the share price is down a whopping 82% in the last twelve months. … Check out our latest analysis for La Jolla Pharmaceutical Given that La Jolla Pharmaceutical didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … When a company doesn't make profits, we'd generally expect to see good revenue growth.

Simply Wall St -

How Should Investors React To La Jolla Pharmaceutical Company's (NASDAQ:LJPC) CEO Pay?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does George Tidmarsh's Compensation Compare With Similar Sized Companies. … Our data indicates that La Jolla Pharmaceutical Company is worth US$202m, and total annual CEO compensation is US$6.5m.

Simply Wall St -

La Jolla Pharmaceutical Company (NASDAQ:LJPC): Immense Growth Potential?

The latest earnings release La Jolla Pharmaceutical Company's (NASDAQ:LJPC) announced in December 2018 … that losses became smaller relative to the prior year's level

Simply Wall St -

Before You Buy La Jolla Pharmaceutical Company (NASDAQ:LJPC), Consider Its Volatility

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

When Will La Jolla Pharmaceutical Company (NASDAQ:LJPC) Become Profitable?

La Jolla Pharmaceutical Company's (NASDAQ:LJPC):. … La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. … View our latest analysis for La Jolla Pharmaceutical

Simply Wall St -

Is La Jolla Pharmaceutical Company (NASDAQ:LJPC) Expensive For A Reason? A Look At The Intrinsic Value

by taking the expected future cash flows and discounting them to today's value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

January Insights Into Healthcare Stocks: La Jolla Pharmaceutical Company (NASDAQ:LJPC)

View our latest analysis for La Jolla Pharmaceutical What’s the catalyst for La Jolla Pharmaceutical's sector growth? … La Jolla Pharmaceutical lags the pack with its negative growth rate of -33.68% over the past year, which indicates the company will be growing at a slower pace than its biotech peers. … If La Jolla Pharmaceutical has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

Does La Jolla Pharmaceutical Company's (NASDAQ:LJPC) Past Performance Indicate A Weaker Future?

After looking at La Jolla Pharmaceutical Company's (NASDAQ:LJPC) latest earnings announcement (30 September 2017), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … See our latest analysis for La Jolla Pharmaceutical How Did LJPC's Recent Performance Stack Up Against Its Past? … For La Jolla Pharmaceutical, its most recent twelve-month earnings is -$101.1M, which, against last year’s figure, has become more negative.

Simply Wall St -

Why La Jolla Pharmaceutical Company (LJPC) Has Zero-Debt On Its Balance Sheet

La Jolla Pharmaceutical Company (NASDAQ:LJPC), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … View our latest analysis for La Jolla Pharmaceutical Is LJPC growing fast enough to value financial flexibility over lower cost of capital? … LJPC’s absence of debt on its balance sheet may be due to lack of access to cheaper capital, or it may simply believe low cost is not worth sacrificing financial flexibility.

Simply Wall St -

LJPC Company Info

Description

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product to treat conditions characterized by iron overload, including hereditary hemochromatosis, beta thalassemia, sickle cell disease, myelodysplastic syndrome, and polycythemia vera. The company was founded in 1989 and is headquartered in San Diego, California.

Details
Name: La Jolla Pharmaceutical Company
LJPC
Exchange: NasdaqCM
Founded: 1989
$250,392,708
27,098,778
Website: http://lajollapharmaceutical.com
Address: La Jolla Pharmaceutical Company
4550 Towne Centre Court,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM LJPC Common Stock Nasdaq Capital Market US USD 03. Jun 1994
DB LJPP Common Stock Deutsche Boerse AG DE EUR 03. Jun 1994
Number of employees
Current staff
Staff numbers
169
La Jolla Pharmaceutical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/15 23:41
End of day share price update: 2019/07/15 00:00
Last estimates confirmation: 2019/06/07
Last earnings filing: 2019/05/06
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.